Zemprocitinib
Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Zemprocitinib is an investigational new drug that is be evaluated by Lynk Pharmaceuticals for the treatment of ankylosing spondylitis and rheumatoid arthritis. It is an janus kinase 1 (JAK1) inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365631136 under CC BY-SA 4.0; modifications have been made.